{"slideshow_credits": null, "snippet": "The company increased its 2014 earnings forecast for a third time, driven in part by revenue gains from its new hepatitis C treatment Olysio.", "abstract": "Johnson & Johnson increases its 2014 earnings forecast for a third time, driven in part by revenue gains from its new hepatitis C treatment Olysio; expects earnings to range from $5.92 to $5.97 a share.", "section_name": "Business Day", "print_page": "2", "document_type": "article", "byline": {"person": [], "organization": "THE ASSOCIATED PRESS", "original": "By THE ASSOCIATED PRESS", "contributor": ""}, "web_url": "http://www.nytimes.com/2014/10/15/business/johnson-johnson-raises-2014-earnings-forecast-again.html", "lead_paragraph": "The company increased its 2014 earnings forecast for a third time, driven in part by revenue gains from its new hepatitis C treatment Olysio.", "headline": {"main": "Johnson &amp; Johnson Raises 2014 Earnings Forecast Again ", "print_headline": "Johnson & Johnson Raises 2014 Earnings Forecast Again", "content_kicker": "Business Briefing"}, "_id": "543e9cd538f0d853e89f62d5", "word_count": "77", "multimedia": [], "pub_date": "2014-10-15T00:00:00Z", "source": "The New York Times", "news_desk": "Business", "keywords": [{"value": "Company Reports", "name": "subject", "is_major": "N", "rank": "1"}, {"value": "Johnson & Johnson", "name": "organizations", "is_major": "Y", "rank": "2"}], "blog": [], "subsection_name": null, "type_of_material": "Brief"}